Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM17OZM)

Drug Name

GL-0817 Drug Info

Synonyms

912762-70-0; MolPort-002-506-765; tert-butyl N-[(2Z)-2-(2,4-dimethoxyphenyl)-2-(hydroxyimino)ethyl]carbamate; ZINC103473003; AKOS005256100; [2-(2,4-DIMETHOXY-PHENYL)-2-HYDROXYIMINO-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER

Indication

Disease Entry	ICD 11	Status	REF
Head and neck cancer	2D42	Phase 2	[1]
Multiple myeloma	2A83	Phase 2	[2]
Oral cavity squamous cell carcinoma	2B6E.0	Phase 2	[3]
Squamous cell carcinoma	2B60-2D01	Phase 2	[1]

Cross-matching ID

PubChem CID: 122706930
CAS Number: CAS 911338-45-9
TTD Drug ID: DM17OZM

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Melanoma-associated antigen 3 (MAGEA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Astuprotimut-R	DMLY0H5	Non-small-cell lung cancer	2C25.Y	Phase 3	[4]
Polynoma-1	DM3QDA6	Melanoma	2C30	Phase 2	[5]
IDM-2101	DMABRXY	Colorectal cancer	2B91.Z	Phase 2	[6]
KITE-718	DMBSI6Y	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
Melanoma vaccine (ALVAC)	DM3HIQY	Melanoma	2C30	Discontinued in Phase 2	[8]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Melanoma-associated antigen 3 (MAGEA3)	TTWSKHD	MAGA3_HUMAN	Immunomodulator	[3]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035081)
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	National Cancer Institute Drug Dictionary (drug id 600553).
5	An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
6	Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25.
7	ClinicalTrials.gov (NCT03139370) Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers. U.S. National Institutes of Health.
8	Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.